secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-057035
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD
------------------------------------------------------------------------

- Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.
- Cash $589M after $337M gross proceeds from upsized follow-on; runway into H1 2027.
- 4D-150 wet AMD: 89% injection burden reduction, 84% patients with 0-1 injections at 24 wks; Phase 3 start Q1 2025.
- Upcoming: 4D-150 broader wet AMD data at ASRS July 2024; 4D-710 CF interim data at ECFS June 2024.
- R&D expenses $27.9M, G&A $10.3M; both up YoY driven by clinical trial progression and headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/0000950170-24-057035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/fdmt-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer